[Measures for allogeneic blood conservation in surgery].
The aim of all efforts to reduce the need of allogeneic blood transfusions is to avoid associated risks. There should particularly be a favourable effect according to the rate of transfusion-transmitted virus infections and immunological side-effects. The acceptance of an individually adjusted lowest haematocrit level and the minimisation of intra-operative blood loss by the application of optimal surgical techniques are among the most essential strategies to reduce or even avoid allogeneic blood transfusions. In addition the following interventions are generally accepted: Preoperative autologous blood donation, where appropriate supported by erythropoietin Preoperative haemodilution, where appropriate supported by erythropoietin Intra- and postoperative blood salvage Topical or systemic pharmacologic interventions to accelerate haemostasis Controlled hypotension Efficacy and indication of the different measures always depend on the individual circumstances of the specific patient. Therefore one should develop an individual approach for every case. In this context the most important subjects are an optimal coordination and if required an appropriate combination of the discussed methods. Algorithms which preoperatively allow approximate calculation of expected transfusion need may be a meaningful tool to facilitate blood conservation planning. However, at the same time one must consider that all strategies to reduce allogeneic transfusion needs are also associated with particular risks. Therefore one has to weigh carefully the pros and cons prior to their application, including the possible alternative of allogeneic transfusion in one's decision making process.
Mansouri Taleghani
B
B
Abteilung für Transfusionsmedizin und Immunhämatologie, Universität Würzburg. behrouz.mansouri@insel.ch
Grossmann
R
R
Reith
H B
HB
Wiebecke
D
D
Thiede
A
A
D016063:Blood Loss, Surgical / Q000503:physiopathology*; D001803:Blood Transfusion; D001804:Blood Transfusion, Autologous; D004921:Erythropoietin / Q000008:administration & dosage*; D006438:Hemodilution; D006801:Humans; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D004921:Erythropoietin